In addition, some small molecular drugs targeting individual PI3K, Akt or mTOR signalling proteins or dual blockade of PI3K and mTOR have been reported to enhance radiosensitivity in prostate cancer, oral squamous cell carcinoma and lung cancer [21, 45, 46]. Here, AKT1 is linked to prostate carcinoma.